The firm posted $29.7 million in revenues, up about 15 percent from $25.8 million in Q4 2018 and slightly above the analysts' average estimate of $29.5 million.
FDA declined to comment on how or when it might respond to the request, which comes as reagent problems delay distribution of tests to public health labs.
The nanosensors will target low-cost, handheld diagnostics and are expected to be able to detect and quantify specific molecules in biofluids in 30 seconds.
The partners are validating three rapid diagnostic test prototypes prior to initiating a trial in the Democratic Republic of the Congo during March 2020.
The urine-based test, which was already available in several markets, does not require any specialized instrumentation and produces results in less than three minutes.
The kits can detect more than 1,000 antimicrobial resistance gene variants, including mobilized colistin resistance (mcr) and extended-spectrum beta lactamases.
LabCorp will be the exclusive provider of the test, which uses next-generation sequencing to look for actionable mutations cell-free DNA in NSCLC patients.
Genetron will provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.
